Zenas BioPharma (NASDAQ:ZBIO) Trading Down 7% – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) traded down 7% during trading on Wednesday . The stock traded as low as $21.44 and last traded at $20.91. 74,846 shares changed hands during trading, a decline of 92% from the average session volume of 995,456 shares. The stock had previously closed at $22.48.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research note on Monday, December 22nd. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, March 17th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Citigroup reduced their price target on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Guggenheim raised their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $44.14.

Zenas BioPharma Stock Performance

The stock has a market capitalization of $1.17 billion, a PE ratio of -2.62 and a beta of -0.54. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a 50 day moving average of $23.28 and a 200-day moving average of $27.30.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In related news, Director Fairmount Funds Management Llc bought 150,000 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was bought at an average price of $20.00 per share, with a total value of $3,000,000.00. Following the purchase, the director directly owned 2,359,025 shares of the company’s stock, valued at approximately $47,180,500. This represents a 6.79% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Hongbo Lu purchased 25,985 shares of the stock in a transaction dated Wednesday, February 11th. The shares were bought at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the acquisition, the director owned 347,968 shares in the company, valued at $7,829,280. This represents a 8.07% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 256,613 shares of company stock valued at $5,178,383. Company insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

A number of institutional investors have recently bought and sold shares of ZBIO. Polar Capital Holdings Plc acquired a new position in Zenas BioPharma in the 4th quarter worth about $38,402,000. Federated Hermes Inc. lifted its holdings in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares during the last quarter. EcoR1 Capital LLC bought a new stake in shares of Zenas BioPharma in the 4th quarter valued at approximately $28,667,000. NEA Management Company LLC increased its holdings in Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after buying an additional 789,500 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new position in Zenas BioPharma in the fourth quarter worth approximately $11,691,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.